P52 | Hyperobese women: what is the best treatment to prevent progression to severe forms of COVID-19 infection?

P. Crispino¹, S. De Taddeo¹, G. Guarisco², G. Aprea¹, A. Palladino¹, C. Galasso¹, M. Testa¹, L. Ottaviani¹, F. Cardoni¹, M. Lichtner³ | ¹UOC Medicina Interna, Ospedale Santa Maria Goretti, Latina, ²UOC Diabetologia, Ospedale Santa Maria Goretti, Latina, ³Dipartimento di Area Medica, Ospedale Santa Maria Goretti, Latina, Italy

Abstract

Background: Obesity is considered one of the main risk factors for the development of a severe form of COVID-19, involving several mechanisms. The present study aimed to evaluate the impact of antiviral agents (AA) and monoclonal antibody therapy (MoAb) in this population.
Methods: We examined 96 female patients (33,9±4,04 years old, BMI: 37,8±6,6 kg), associated with other age-related comorbidities, treated for COVID-19 infection, evaluating the times to negativization (TN) and the long-term sequelae. Values are given as medians and non-parametric Mann–Whitney tests were applied to compare the differences in values. All statistical analyses were considered significant with p-values<0.05.
Results: Comparing patients treated with MoAb s vs. AA, the median TN is 16 vs. 8 days (z-score is -3.09; p:0.002). Comparing vaccinated vs. unvaccinated patients, the median TN is 9 vs. 18.5 days (z-score is -3.18; p: 0.001. In unvaccinated patients, the median TN was 19 days in the MoAb group vs. 15 days in the AA group (z-score is 0.2; p:0.83). MoAb in vaccinated vs. unvaccinated patients, showed a median TN of 14 vs. 19 days (z-score is -0.64; p:0.51. Comparing AA in vaccinated vs. unvaccinated the median TN is 7.5 vs. 15 days (z-score -3; p:0.0027).
Conclusions: In hyperobese female patients who have risk factors for progression to severe disease, vaccination is recommended. Compared to MoAbs, AA obtains a significantly shorter eradication time of COVID-19 and therefore fewer short and long-term sequelae.